Akebia Therapeutics
AKBA
130 hedge funds and large institutions have $360M invested in Akebia Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 32 closing their positions.
914% more call options, than puts
Call options by funds: $8.21M | Put options by funds: $810K
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
3.9% less ownership
Funds ownership: 75.42% → 71.53% (-3.9%)
10% less funds holding
Funds holding: 145 → 130 (-15)
15% less capital invested
Capital invested by funds: $423M → $360M (-$63M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$10M |
| 2 |
ClearBridge Investments
New York
|
+$9.09M |
| 3 |
Morgan Stanley
New York
|
+$4.44M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.06M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$28.2M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$20.6M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$3.72M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$3.44M |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$1.67M |
AKBA Hedge Fund Activity: Q3 2018 in Review
130 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2018, worth a combined $360M — down 15% from $423M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of AKBA and 17 opened new positions — a net loss of 15 holders — while 42 trimmed existing stakes and 43 added.
The largest buyer was Abrams Capital Management, opening a new position worth an estimated $10M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $28.2M sold.
- 130 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2018, down from 145 in Q2 2018.
- Funds reported $360M of Akebia Therapeutics stock for Q3 2018, down 15% quarter-over-quarter.
- 17 funds opened new Akebia Therapeutics positions in Q3 2018 and 32 closed out, a net change of -15 holders.
- The largest Akebia Therapeutics buyer in Q3 2018 was Abrams Capital Management, an estimated $10M added.
- The largest Akebia Therapeutics seller in Q3 2018 was Eagle Asset Management, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2018.